FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Factor VIII inhibitor bypassing fraction (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms FEIBA PROOF
- Sponsors Baxter Healthcare Corporation
Most Recent Events
- 10 Oct 2014 New source identified and integrated (European Clinical Trial database; EudraCT2008-003855-65)
- 01 Apr 2014 New trial record